UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2025
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes ☐ No
☒
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”)
published one announcement (the “Public Notice”) to the Australian Securities Exchange on March 13, 2025 titled:
|
|
- |
“Participation in Leerink, NWR healthcare conferences” |
A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.
This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
EXHIBITS
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
RADIOPHARM THERANOSTICS LIMITED |
|
|
Date: March 13, 2025 |
By: |
/s/ Phillip Hains |
|
|
Phillip Hains |
|
|
Company Secretary |
3
Exhibit
99.1
ASX ANNOUNCEMENT
13 MARCH 2025 |
 |
RADIOPHARM
PARTICIPATION IN LEERINK, NWR HEALTHCARE CONFERENCES
Sydney, Australia – 13 March 2025 – Radiopharm Theranostics
(ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class
platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce ongoing and upcoming conference
participation.
Radiopharm’s Chief Medical Officer Dr Dimitris Voliotis is participating
in the Leerink Partners Global Healthcare Conference 2025 in Miami, Florida, USA this week, taking numerous meetings with a range of professional
and institutional investors.
Additionally, Dr Voliotis will present at the NWR Virtual Healthcare
Conference at 9:40am AEDT on Wednesday 19 March 2025.
Shareholders, investors and interested parties are encouraged to register
to attend the presentation at the following link: https://us02web.zoom.us/webinar/register/WN_I3oC9hkOSmiUVa_fJhybCw
A recording will be available at the above link shortly after the conclusion
of the live session, and the replay will also be available via the Company’s website and social media channels.
Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au
For more information please visit: https://nwrcommunications.com/healthconf
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company
developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high
unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a deep pipeline of highly differentiated
molecules spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development.
The pipeline has been built based on the potential to be first-to-market or best-in-class. The clinical program includes one Phase II
and three Phase I trials in a variety of solid tumour cancers including brain, lung, breast and pancreas. Learn more at radiopharmtheranostics.com.
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
ASX ANNOUNCEMENT
13 MARCH 2025 |
 |
Authorized on behalf of the Radiopharm Theranostics Board of Directors
by Executive Chairman Paul Hopper.
For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Radiopharm Theranostics (PK) (USOTC:RDPTF)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Radiopharm Theranostics (PK) (USOTC:RDPTF)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025